Latest research on Victoza

Victoza contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.

Latest findings

During hospitalization, patients in CSII alone group received insulin Aspart (NovoRapid, Novo Nordisk, Bagsværd, Denmark) or insulin lispro (Humalog, Eli Lilly, USA) with an insulin pump (MiniMed 712, Medtronic, Northridge, CA) as CSII therapy, while the CSII + Lira group received liraglutide (Victoza, Novo Nordisk, Bagsvaerd, Denmark) 0.6 mg per day in addition to aforementioned CSII regimen. [source, 2016]
For diabetes, we found that the reviews for seven drugs (Apidra, Symlin, Exubera, Januvia, Janumet, Victoza and Bydureon) discussed the rationale for use of surrogates and three of them (Symlin, Victoza and Bydureon) justified choosing glycaemic control as an outcome by clearly stating the evidence that corresponds to the highest level of evidence for surrogacy using the ICH-9 criteria. [source, 2015]
For example, in the review of Victoza, the reviewer stated that “HbA1c has excellent reliability, predicts several diabetes-specific complications, and provides the current basis for treatment decisions. [source, 2015]
We found that a review for one drug in COPD (Arcapta Neohaler) mentioned a MID and reviews for 12 drugs in diabetes (Avandaryl, Symlin, Duetact, Exubera, Januvia, BYETTA, Cycloset, Onglyza, Kombiglyze XR, Victoza, Tradjenta and Bydureon) mentioned a threshold (number of patients achieving the target haemoglobin A1C level) that is linked to patient-centred outcomes. [source, 2015]
Finally, the BEGIN Victoza Add-On study28 compared IDeg + IAsp versus IDeg + liraglutide in a T2DM population from the BEGIN Once Long extension cohort. [source, 2015]
The efficacy and safety of adding long-acting GLP1RA liraglutide OD versus adding short-acting insulin Aspart (IAsp) OD to long-acting insulin degludec (IDeg) OD + metformin in subjects with T2DM was first investigated in the BEGIN: Victoza ADD-ON trial [16]. [source, 2015]
On December 23, 2014, the FDA announced approval of a higher dose version of liraglutide (trade name Saxenda) for the treatment of chronic weight management. [source, 2015]
Liraglutide, another long-acting GLP-1 receptor agonist, was developed by Novo Nordisk and marketed under the brand name Victoza. [source, 2015]
With such beneficial properties, GLP-1 analogues are commonplace in the glycaemic control of patients with type 2 diabetes mellitus (T2DM) and presently four drugs within this class are licensed for use in T2DM: exenatide (Byetta) [10], liraglutide (Victoza) [11], lixisenatide (Lyxumia) [12], and prolonged-release exenatide (Bydureon) [13]. [source, 2015]
This has indeed been the case; for example, in the Victoza ADD-ON study (NCT01388361), addition of the GLP-1RA liraglutide to insulin degludec resulted in greater reductions in glycated hemoglobin (HbA1c) at 26 weeks relative to adding a single daily dose of insulin Aspart [12]. [source, 2015]